Air Canada is facing a potential nationwide flight cancellation due to a threatened strike by its flight attendants, with the airline initiating a phased wind-down of operations starting Thursday. The dispute centers on pay and compensation for ground time, with the union rejecting a proposal for binding arbitration and voting 99.7% in favor of striking. If the strike occurs on Saturday, Air Canada will suspend all its Air Canada and Air Canada Rouge flights, though regional operations via Jazz Aviation and PAL Airlines will continue. The airline has notified impacted passengers via email or text and will offer refunds or alternative travel options, but cannot compensate for food and lodging due to federal regulations. Passengers can reschedule flights between Aug. 21 and Sept. 12 at no cost. The conflict has been ongoing for eight months, with both sides disagreeing on a pay raise and the compensation for time spent on the ground during boarding.

Werewolf Therapeutics, Inc. has published its Form 10-Q report for the second quarter of 2025, detailing its financial performance and business developments. The company reported an operating loss of $17.5 million, a net loss of $18.0 million, and no collaboration revenue for the period. It continues to advance its INDUKINE and INDUCER molecules, including WTX-124 in a Phase 1/1b trial and WTX-330 in a Phase 1b/2 trial. The company is expanding its PREDATOR platform with new preclinical candidates and has completed material performance obligations under its collaboration with Jazz Pharmaceuticals. Future plans include presenting interim trial data and exploring strategic alliances.

Jazz Pharmaceuticals reported Q2 2025 financial results showing strong revenue growth in its neuroscience portfolio, particularly from Xywav, despite challenges in oncology due to competitive pressures and inventory issues. The company revised its full-year revenue guidance downward to $4.23 billion and raised its Adjusted EPS guidance to $5.20. Management highlighted ongoing investments in patient education and field initiatives to support product growth. Analyst questions focused on Xywav's patient acquisition, Zepzelca's competitive landscape, zanidatamab data release details, Epidiolex's market potential, and the impact of tariffs and potential Most Favored Nation drug pricing changes. Key regulatory and clinical milestones, including FDA approval of dordaviprone, label expansion of Zepzelca for first-line maintenance use, and Phase III data for zanidatamab, are expected to influence future performance. The company trades at $115.47, up from $113.05 prior to earnings. The article also references broader market trends, including Donald Trump's April 2025 tariffs and a curated list of high-performing stocks from StockStory.

DelveInsight's 'Myelodysplastic Syndrome Pipeline Insights 2025' report offers a comprehensive analysis of over 120 companies and 150 pipeline drugs in the MDS therapeutic landscape. The report evaluates drug development by stage, product type, route of administration, and molecule class, highlighting both active and inactive therapies. Key clinical trials include Novartis's study on eltrombopag monotherapy in Japanese patients with lower-risk MDS and H. Lee Moffitt Cancer Center's Phase 1b/2 trial of canakinumab with darbepoetin alfa in patients who have failed prior ESA therapy. Promising therapies under development include Tamibarotene, RVU120, Emavusertib, and MNV-201. The report also details collaborations, licensing agreements, and financing activities influencing the MDS market, with global coverage and insights into unmet needs, market drivers, and future trends.

DelveInsight's 2025 Myelodysplastic Syndrome (MDS) Pipeline Report provides a comprehensive analysis of 120+ companies and 150+ pipeline therapies in the MDS treatment space. The report covers clinical and nonclinical stage drug developments, including therapies in phases I, II, and III, by product type, route of administration, and molecular mechanism. It highlights key companies such as Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, and Minovia Therapeutics, detailing their pipeline drugs like tamibarotene, RVU120, emavusertib, and MNV-201. The report also outlines ongoing clinical trials, including a Phase 1b/2 study by H. Lee Moffitt Cancer Center evaluating canakinumab with darbepoetin alfa in lower-risk MDS patients, and a Phase III trial by Syros Pharmaceuticals for tamibarotene in higher-risk MDS. Additionally, it details collaborations, therapeutic assessments, and inactive pipeline products, offering insights into market trends, unmet needs, and future directions in MDS treatment.